AstraZeneca’s Tagrisso divides on immediate adoption in adjuvant non-small cell lung cancer

18th June 2020 (Last Updated June 18th, 2020 08:01)

AstraZeneca’s Tagrisso (osimertinib) may not find widespread adoption in the adjuvant setting for non-small cell lung cancer (NSCLC), regardless of positive Phase III data, in the absence of a consensus on whether data suggesting a survival benefit is required.

The Phase III (NCT02511106) ADAURA study data was presented at the American Society of Clinical Oncology (ASCO) Virtual Meeting plenary session last month. Read more here.